Status:
COMPLETED
Clinical Performance of Abbott RealTime Hepatitis C Virus (HCV) Genotype II Test
Lead Sponsor:
National Taiwan University Hospital
Collaborating Sponsors:
Abbott Diagnostics Division
National Science and Technology Council, Taiwan
Conditions:
Hepatitis C
Eligibility:
All Genders
18+ years
Brief Summary
Hepatitis C virus (HCV) infection, a leading cause of cirrhosis, hepatocellular carcinoma (HCC) and liver transplantation, affects approximately 170 million individuals worldwide. Combination of pegin...
Detailed Description
Hepatitis C virus (HCV) infection, a leading cause of cirrhosis, hepatocellular carcinoma (HCC) and liver transplantation, affects approximately 170 million individuals worldwide. Therefore, preventio...
Eligibility Criteria
Inclusion
- HCV patients with both positive for anti-HCV and HCV RNA (Cobas Taqman, Roche Diagnostics, LOQ:25 IU/mL and LOD:10 IU/mL)
- Patients with signed informed consent
Exclusion
- Patients without signed informed consent
- HCV patients without detectable HCV RNA (Cobas Taqman, Roche Diagnostics)
Key Trial Info
Start Date :
July 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2013
Estimated Enrollment :
255 Patients enrolled
Trial Details
Trial ID
NCT00979979
Start Date
July 1 2009
End Date
October 1 2013
Last Update
October 21 2014
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital, Yun-Lin Branch
Douliu, Taiwan
2
Far Eastern Memorial Hospital
Taipei, Taiwan
3
National Taiwan University Hospital
Taipei, Taiwan
4
Taipei Municipal Hospital, Ren-Ai Branch
Taipei, Taiwan